When should we use it? The role of brentuximab vedotin in 2024

2.

Phillips

EH

,

Kirkwood

AA

,

Hague

C

, et al.

Bleomycin affects lung function for at least 5 years after treatment for Hodgkin lymphoma-data from the international, randomised phase 3 Rathl trial

.

Blood

.

2023

;

142

(

Suppl 1

):

612

.

3.

Ansell

SM

,

Radford

J

,

Connors

JM

, et al;

ECHELON-1 Study Group

.

Overall survival with brentuximab vedotin in stage III or IV Hodgkin's Lymphoma

.

N Engl J Med

.

2022

;

387

(

4

):

310

-

320

.

4.

Borchmann

P

,

Goergen

H

,

Kobe

C

, et al.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

.

Lancet

.

2017

;

390

(

10114

):

2790

-

2802

.

5.

Eichenauer

DA

,

Plütschow

A

,

Kreissl

S

, et al.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

.

Lancet Oncol

.

2017

;

18

(

12

):

1680

-

1687

.

6.

Damaschin

C

,

Goergen

H

,

Kreissl

S

, et al.

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

.

Leukemia

.

2022

;

36

(

2

):

580

-

582

.

7.

Borchmann

P

,

Ferdinandus

J

,

Schneider

G

, et al;

German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open- label, phase 3 trial

.

Lancet

.

2024

;

404

(

10450

):

341

-

352

.

8.

Neppelenbroek

SIM

,

Geurts

YM

,

Aleman

BMP

, et al.

Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin Lymphoma

.

J Clin Oncol

.

2024

;

42

(

16

):

1903

-

1913

.

9.

Hutchings

M

,

Balari

A

,

Carvalho

S

, et al.

EORTC-1537-COBRA: very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

.

Hemasphere

.

2024

.

10.

Straus

DJ

,

Długosz-Danecka

M

,

Connors

JM

, et al.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

.

Lancet Haematol

.

2021

;

8

(

6

):

e410

-

e421

.

11.

Herrera

AF

,

LeBlanc

ML

,

Castellino

SM

, et al.

SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)

.

J Clin Oncol

.

2023

;

41

(

17_Suppl

):

LBA4

.

12.

Rutherford

SC

,

Li

H

,

Herrera

AF

, et al.

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826

.

Blood

.

2023

;

142

(

Suppl 1

):

181

.

13.

Abdel-Wahab

N

,

Shah

M

,

Lopez-Olivo

MA

,

Suarez-Almazor

ME

.

Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review

.

Ann Intern Med

.

2018

;

168

(

2

):

121

-

130

.

14.

Yamaguchi

T

,

Shimizu

J

,

Hasegawa

T

, et al.

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

.

BMC Cancer

.

2021

;

21

(

1

):

924

.

15.

Abdel-Wahab

N

,

Safa

H

,

Abudayyeh

A

, et al.

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

.

J Immunother Cancer

.

2019

;

7

(

1

):

106

.

16.

Johnson

DB

,

Nebhan

CA

,

Moslehi

JJ

,

Balko

JM

.

Immune-checkpoint inhibitors: long-term implications of toxicity

.

Nat Rev Clin Oncol

.

2022

;

19

(

4

):

254

-

267

.

17.

Radford

J

,

Illidge

T

,

Counsell

N

, et al.

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma

.

N Engl J Med

.

2015

;

372

(

17

):

1598

-

1607

.

18.

Fuchs

M

,

Goergen

H

,

Kobe

C

, et al.

Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group

.

J Clin Oncol

.

2019

;

37

(

31

):

2835

-

2845

.

19.

André

M

,

Girinsky

T

,

Federico

M

, et al.

Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial

.

J Clin Oncol

.

2017

;

35

:

1786

-

1794

.

20.

Fornecker

L-M

,

Lazarovici

J

,

Aurer

I

, et al;

LYSA-FIL-EORTC

Intergroup

.

Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin Lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial

.

J Clin Oncol

.

2023

;

41

(

2

):

327

-

335

.

21.

Kumar

A

,

Casulo

C

,

Advani

RH

, et al.

Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma

.

J Clin Oncol

.

2021

;

39

(

20

):

2257

-

2265

.

22.

Stuver

R

,

Michaud

L

,

Casulo

C

, et al.

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: extended follow-up with evaluation of baseline metabolic tumor volume and PET2

.

Blood

.

2022

;

140

(

Suppl 1

):

1756

-

1758

.

23.

Abramson

JS

,

Bengston

E

,

Redd

R

, et al.

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

.

Blood Adv

.

2023

;

7

(

7

):

1130

-

1136

.

24.

Park

SI

,

Shea

TC

,

Olajide

O

, et al.

ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma

.

Blood Advances

.

2020

;

4

(

11

):

2548

-

2555

.

25.

Moskowitz

CH

,

Matasar

MJ

,

Zelenetz

AD

, et al.

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

.

Blood

.

2012

;

119

(

7

):

1665

-

1670

.

26.

Chen

R

,

Palmer

JM

,

Martin

P

, et al.

Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2015

;

21

(

12

):

2136

-

2140

.

27.

Chen

R

,

Palmer

J

,

Martin

P

, et al.

Post transplant outcome of a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT

.

Blood

.

2015

;

126

(

23

):

519

.

28.

LaCasce

AS

,

Bociek

RG

,

Sawas

A

, et al.

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

.

Br J Haematol

.

2020

;

189

(

3

):

e86

-

e90

.

29.

Lynch

RC

,

Cassaday

RD

,

Smith

SD

, et al.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

.

Lancet Haematol

.

2021

;

8

(

8

):

e562

-

e571

.

30.

Kersten

MJ

,

Driessen

J

,

Zijlstra

JM

, et al.

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

.

Haematologica

.

2021

;

106

(

4

):

1129

-

1137

.

31.

Garcia-Sanz

R

,

Sureda

A

,

de la Cruz

F

, et al.

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

.

Ann Oncol

.

2019

;

30

(

4

):

612

-

620

.

32.

Moskowitz

AJ

,

Schöder

H

,

Yahalom

J

, et al.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

.

Lancet Oncol

.

2015

;

16

(

3

):

284

-

292

.

33.

Herrera

AF

,

Palmer

J

,

Martin

P

, et al.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

.

Ann Oncol

.

2018

;

29

(

3

):

724

-

730

.

34.

Advani

RH

,

Moskowitz

AJ

,

Bartlett

NL

, et al.

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

.

Blood

.

2021

;

138

(

6

):

427

-

438

.

35.

Diefenbach

CS

,

Jegede

O

,

Ansell

SM

, et al.

Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412)

.

Blood

.

2023

;

142

(

Suppl 1

):

607

.

36.

Arai

S

,

Fanale

M

,

deVos

S

, et al.

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

.

Leuk Lymphoma

.

2013

;

54

(

11

):

2531

-

2533

.

37.

Moskowitz

CH

,

Walewski

J

,

Nademanee

A

, et al.

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

.

Blood

.

2018

;

132

(

25

):

2639

-

2642

.

38.

Falade

AS

,

Redd

RA

,

Shah

H

, et al.

Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma with and without pre-transplant exposure to novel agents

.

Blood

.

2023

;

142

(

Suppl 1

):

3062

.

39.

Marouf

A

,

Cottereau

AS

,

Kanoun

S

, et al.

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

.

Haematologica

.

2022

;

107

(

7

):

1681

-

1686

.

40.

Martínez

C

,

de Haro

ME

,

Romero

S

, et al;

Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH)

.

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

.

Ann Hematol

.

2023

;

102

(

2

):

429

-

437

.

41.

Wagner

CB

,

Boucher

K

,

Nedved

A

, et al.

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

.

Haematologica

.

2023

;

108

(

11

):

3025

-

3032

.

42.

Stamatoullas

A

,

Brice

P

,

Bouabdallah

R

, et al.

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly

.

Br J Haematol

.

2015

;

170

(

2

):

179

-

184

.

43.

Connors

JM

,

Jurczak

W

,

Straus

DJ

, et al;

ECHELON-1 Study Group

.

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's Lymphoma

.

N Engl J Med

.

2018

;

378

(

4

):

331

-

344

.

44.

Evens

AM

,

Advani

RH

,

Helenowski

IB

, et al.

Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma

.

J Clin Oncol

.

2018

;

36

(

30

):

3015

-

3022

.

45.

Friedberg

JW

,

Bordoni

RE

,

Patel-Donnelly

D

, et al.

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy

.

Blood

.

2024

;

143

(

9

):

786

-

795

.

46.

Radford

J

,

Adedayo

T

,

Ardavan

A

, et al.

P025: RADAR: an international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+ AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma

.

HemaSphere

.

2022

;

6

:

12

-

13

.